You just read:

Formation Biologics Announces Dosing of First Patient in a Phase I/IIa Trial of AVID100, Closing of Series B Financing, and Appointment of Dr. Anthony Tolcher to its Board of Directors

News provided by

Formation Biologics

May 15, 2017, 08:00 ET